JB
Jade Biosciences, Inc.
JBIO · NASDAQ
$16.74 -2.22% (-$0.38)
1M -21.52%
Market Cap $1.21B
P/E Ratio -
Div. Yield -
ROE 49.11%
Bulios Fair Price
$14.43
13.8% downside
Current Price
$16.74
Undervalued Fair Value Overvalued
According to Bulios Fair Price, JBIO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
71 /100
Cheap P/B 2.75x
P/E N/A
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 37.92%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 37.42%
Asset turnover 0.00x
ROE 49.11%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 14.93x
Int. coverage N/A
Stability
22 /100
Unstable Beta 1.45x
Profitable years 0
EPS volatility 66.27%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about JBIO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Tom Frohlich
Employees
55
Headquarters
Waltham
Upcoming events
12 NOV
Earnings
Upcoming earnings report